Other genetic mutations affecting the NF-κB pathway in CLL include: NFKBIE mutations (causing a reduction in the activity of the negative regulator of NF-κB: IκBε), BIRC3 mutations (causing an increase in NIK levels) and MYD88 mutations (causing constitutive signaling in the TLR signaling pathway) (35–37). Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.